drugset / Trial / NCT06241638

Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers

NCT06241638

Completed 80 enrolled Al-Balqa Applied University
RandomizedParallel-groupSingle-blindBasic science

Summary

The current study was conducted to evaluate the prognostic implications of vitamin B12 admission on BMI and HbA1c levels in type 2 diabetic patients treated with Dapagliflozin as a routine medication.

Timeline

Start
2022-07-01
Primary completion
2023-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject methylcobalamin Small molecule 500 ug Oral
Background Dapagliflozin Small molecule 10 mg Oral

Indications